Company

Ordering
INQUIRY
  1. Home
  2. Disease Models
  3. Otology Disease Models
  4. Cisplatin-Induced Hearing Loss (CIHL) Model

Cisplatin-Induced Hearing Loss (CIHL) Model

Creative Bioarray has established a robust Cisplatin-Induced Hearing Loss (CIHL) Model to support the investigation of ototoxicity mechanisms and accelerate the development of effective hearing protection therapies.

What is Cisplatin-Induced Hearing Loss (CIHL)?

Cisplatin-induced hearing loss (CIHL) is a major dose-limiting side effect of cisplatin, a widely used chemotherapeutic agent. It typically presents as irreversible, bilateral, high-frequency sensorineural hearing loss, affecting up to 60% of patients. Cisplatin causes hair cell death by forming DNA adducts, mitochondrial dysfunction, oxidative stress, and inflammation, culminating in programmed cell death by apoptosis, necroptosis, pyroptosis, or ferroptosis. Current clinical management is limited to prosthetic devices such as hearing aids, which cannot repair cochlear damage, highlighting the urgent need for effective protective strategies and reliable preclinical models.

Fig. 1: Molecular pathways of cisplatin-induced cochlear damage.

Fig. 1: Molecular mechanisms of cisplatin-induced ototoxicity. (Tang et al., 2021)

Creative Bioarray's Cisplatin-Induced Hearing Loss (CIHL) Model

  • Available Animal
    • Rat
    • Mouse
  • Modeling Method

All animals receive cisplatin treatment to induce a hearing loss model.

  • Route of Administration
    • Middle Ear: Tympanic membrane puncture (TT), bulla osteotomy
    • Inner Ear: Round window membrane administration (RWM), posterior semicircular canal administration (PSC), cochleostomy
  • Endpoints
    • Auditory brainstem response (ABR) measurement
    • Distortion product otoacoustic emission (DPOAE)
    • Histology analysis of cochlea
    • qPCR or Western blot
    • Customized endpoints tailored to your specific research requirements

Example Data

Fig. 2: CPI-455 prevents hearing loss via hair cell protection.

Fig. 2: CPI-455 protected against CP-induced hearing loss in vivo. A Experimental workflow. B ABR analysis. C Graphical representation of the number of Myosin 7a-positive HCs. D-F Cochleae were stained with Myosin 7a (red) and DAPI (blue). Scale bar 10 µm. (Liu et al., 2022)

Quotation and Ordering

Creative Bioarray is committed to supporting auditory research with reliable, well-characterized in vivo models. For pricing, technical consultation, or to place an order, please contact us directly. Our team is ready to assist you in customizing a study that fits your specific needs.

References

  1. Tang, Q., et al. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm. 2021;163:60-71.
  2. Liu, C., et al. Inhibition of KDM5A attenuates cisplatin-induced hearing loss via regulation of the MAPK/AKT pathway. Cell Mol Life Sci. 2022;79(12):596.

For research use only. Not for any other purpose.

Disease Models

Online Inquiry